AMSTERDAM, April 6 (Reuters) - The European medicines
watchdog expects to hold a press conference this week updating
the public on its review of rare blood clotting cases in people
who have received the AstraZeneca COVID-19 vaccine, a
spokeswoman said on Tuesday.
In an emailed response to questions, a spokeswoman for the
European Medicines Agency said its pharmaceuticals risk
assessment committee has not reached a conclusion in its current
review of the vaccine's safety, and it expects to hold a press
briefing "as soon as the review is finalized," either on April 7
or April 8.
(Reporting by Toby Sterling; editing by David Evans)
Astrazeneca (AZN)
